Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 6
2016 4
2018 8
2019 5
2020 4
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Fluticasone furoate/vilanterol versus fluticasone propionate in patients with asthma and exercise-induced bronchoconstriction.
Martin N, Weiler JM, Pearlman D, Jacques L, Nunn C, Forth R, West S, Dunn K, O'Byrne PM. Martin N, et al. J Asthma. 2020 Apr;57(4):431-440. doi: 10.1080/02770903.2019.1579344. Epub 2019 Feb 22. J Asthma. 2020. PMID: 30795705 Clinical Trial.
Objective: To investigate whether once-daily (OD) fluticasone furoate (FF)/vilanterol (VI) provides greater long-term protection from postexercise fall in forced expiratory volume in 1 s (FEV(1)) than twice-daily (BD) fluticasone propionate (FP) in patients with asthma and …
Objective: To investigate whether once-daily (OD) fluticasone furoate (FF)/vilanterol (VI) provides greater long-term protection from …
Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults.
Li Y, Li H, Sheng Y, Du X, Yao Y, Luo X, Ma P. Li Y, et al. Clin Pharmacol Drug Dev. 2019 Aug;8(6):721-733. doi: 10.1002/cpdd.626. Epub 2018 Nov 14. Clin Pharmacol Drug Dev. 2019. PMID: 30427594 Clinical Trial.
The pharmacokinetics (PK) and safety of single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) after single and repeat dosing in healthy Chinese adults were assessed. ...
The pharmacokinetics (PK) and safety of single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) after single and repe …
Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
Stynes G, Svedsater H, Wex J, Lettis S, Leather D, Castelnuovo E, Detry M, Berry S. Stynes G, et al. Respir Res. 2015 Feb 15;16(1):25. doi: 10.1186/s12931-015-0184-8. Respir Res. 2015. PMID: 25849223 Free PMC article. Review.
BACKGROUND: Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment approved in the United States, Canada and Europe for the long-term maintenance therapy of COPD. ...
BACKGROUND: Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily inhaled corticosteroid (ICS)/long-acting beta2 agonis …
Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk.
Calverley PMA, Anderson JA, Brook RD, Crim C, Gallot N, Kilbride S, Martinez FJ, Yates J, Newby DE, Vestbo J, Wise R, Celli BR; SUMMIT (Study to Understand Mortality and Morbidity) Investigators. Calverley PMA, et al. Am J Respir Crit Care Med. 2018 Jan 1;197(1):47-55. doi: 10.1164/rccm.201610-2086OC. Am J Respir Crit Care Med. 2018. PMID: 28737971 Clinical Trial.
OBJECTIVES: In a prespecified analysis of the key secondary outcome in SUMMIT (Study to Understand Mortality and Morbidity), we investigated whether the inhaled corticosteroid fluticasone furoate (FF; 100 mug), the long-acting beta-agonist vilanterol (VI; 25 mug), or their …
OBJECTIVES: In a prespecified analysis of the key secondary outcome in SUMMIT (Study to Understand Mortality and Morbidity), we investigated …
Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities.
Kalhan R, Slade D, Ray R, Moretz C, Germain G, Laliberté F, Shen Q, Duh MS, MacKnight SD, Hahn B. Kalhan R, et al. Int J Chron Obstruct Pulmon Dis. 2021 Apr 22;16:1149-1161. doi: 10.2147/COPD.S298032. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 33911860 Free PMC article.
This study compared COPD-related medical costs and exacerbations in high-cost, high-comorbidity patients with COPD receiving initial maintenance treatment (IMT) with umeclidinium/vilanterol (UMEC/VI) versus fluticasone propionate/salmeterol (FP/SAL), budesonide/formoterol …
This study compared COPD-related medical costs and exacerbations in high-cost, high-comorbidity patients with COPD receiving initial mainten …
Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system.
Balmaceda C, Espinoza MA, Abbott T, Peters A. Balmaceda C, et al. Expert Rev Pharmacoecon Outcomes Res. 2022 Jul;22(5):743-751. doi: 10.1080/14737167.2022.2044308. Epub 2022 Mar 6. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 35176212
OBJECTIVES: The cost-effectiveness of single-inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) was compared to the treatments Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinio/Vilanterol (UMEC/VI) and Fluticasone Pro …
OBJECTIVES: The cost-effectiveness of single-inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/V …
Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study.
Jacques L, Bakerly ND, New JP, Svedsater H, Lay-Flurrie J, Leather DA. Jacques L, et al. J Asthma. 2019 Jul;56(7):748-757. doi: 10.1080/02770903.2018.1490751. Epub 2018 Oct 16. J Asthma. 2019. PMID: 29972089 Clinical Trial.
OBJECTIVE: The Asthma Salford Lung Study demonstrated the effectiveness of initiating once-daily fluticasone furoate/vilanterol (FF/VI) versus continuing usual care in asthma patients in UK primary care [ 1 ]. ...
OBJECTIVE: The Asthma Salford Lung Study demonstrated the effectiveness of initiating once-daily fluticasone furoate/vilanterol (FF/V …
Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial.
Singh D, Worsley S, Zhu CQ, Hardaker L, Church A. Singh D, et al. BMC Pulm Med. 2015 Aug 19;15:91. doi: 10.1186/s12890-015-0092-1. BMC Pulm Med. 2015. PMID: 26286141 Free PMC article. Clinical Trial.
BACKGROUND: Umeclidinium (UMEC; long-acting muscarinic antagonist) plus vilanterol (VI; long-acting beta2 agonist [LABA]) and the LABA/inhaled corticosteroid fluticasone propionate/salmeterol (FP/SAL) are approved maintenance treatments for chronic obstructive pulmonary di …
BACKGROUND: Umeclidinium (UMEC; long-acting muscarinic antagonist) plus vilanterol (VI; long-acting beta2 agonist [LABA]) and the LAB …
Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
Bernstein D, Andersen L, Forth R, Jacques L, Yates L. Bernstein D, et al. J Asthma. 2018 Sep;55(9):984-993. doi: 10.1080/02770903.2017.1386214. Epub 2018 Apr 13. J Asthma. 2018. PMID: 28961020 Clinical Trial.
OBJECTIVE: We aimed to demonstrate non-inferiority of once-daily fluticasone furoate/vilanterol 100/25 g (FF/VI) to twice-daily fluticasone propionate/salmeterol 250/50 g (FP/SAL) in adults/adolescents with asthma well controlled on inhaled corticosteroid/long-acting beta( …
OBJECTIVE: We aimed to demonstrate non-inferiority of once-daily fluticasone furoate/vilanterol 100/25 g (FF/VI) to twice-daily fluti …
25 results